Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications